Replies to post #114819 on Biotech Values

[RockRat]

PRO 140 has shown decent results in studies, but an injectable for HIV = commercial dud, niche market at best for non-responders to other treatments, maybe. Whatever happened to PRO 206, the small molecule entry inhibitor for HepC? They still show the entry inhibitors as preclinical candidates on their pipe chart, but no mention of PRO206 directly.

They announced its selection for clinical development over two years ago. Suspiciously slow. Dubious about PGNX as an investment.

Regards, RockRat

[jq1234]

The Relistor oral phase III isn't that far along, so I think there will still be significant costs paid by Salix and this remaining a financial overhang from PGNX.

PGNX at least spent more than 25% total cost on oral trial already. Trial prepration and initiation cost a lot.

PGNX now has cash, and thus the option to run a phase III PRO140 trial if they desire.

I don't think PGNX should spend their own money run trial on 140. Its current approach is right one, let interest group put the money run trial on small set patients, IV drug users for example. In today's triple and quad pill age, injectable doesn't have much market potential. Up to today, 140 was developed on grant money.

I do tip my hat to you and feel a bit of jealous when I read you sold your PGNX at $15.

Remember, I got chastised for talking about Relistor's revenue projection after initial approval by everyone was too high. I didn't consider PGNX as long term hold back then, thus luckily took profit. PGNX should be fine from now on. It was victim of WYE/PFE merger, basically couldn't do anything for 2 years. It starts anew from now. PSMA ADC and C diff mab are interesting early candidates.